Insmed reports first-quarter 2025 financial results and provides business update

—arikayce® (amikacin liposome inhalation suspension) total revenue of $92.8 million for the first quarter of 2025, reflecting 23% growth over the first quarter of 2024— —nda for brensocatib in patients with bronchiectasis remains on track, with a pdufa target action date of august 12, 2025— —phase 2b study of tpip in patients with pah completed; topline data expected in june 2025— —enrollment completed for phase 2b birch study of brensocatib in patients with crssnp; topline data anticipated by the end of 2025— —maa filings for brensocatib in patients with bronchiectasis accepted by ema and mhra— —company reiterates 2025 global arikayce revenue guidance range of $405 million to $425 million, reflecting double-digit growth compared to 2024— bridgewater, n.j. , may 8, 2025 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended march 31, 2025 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking